Serum Life Science Europe GmbH

SIILTIBCY Receives Positive CHMP Opinion for Tuberculosis Detection in Europe

• The European Medicines Agency's CHMP has recommended SIILTIBCY, a novel tuberculosis skin test, for approval in Europe. • SIILTIBCY is designed to accurately detect TB, irrespective of prior BCG vaccination status, addressing a key diagnostic challenge. • Phase 3 clinical trials involving over 2,500 participants demonstrated the accuracy and safety of SIILTIBCY in diagnosing TB. • Upon European Commission approval, SIILTIBCY will be available in EU Member States, with SLS Europe managing authorization and BBio handling distribution.